Loading
NRX Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Dec 2024.
NRX Pharmaceuticals, Inc.: what insiders have been doing
NRX Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at NRX Pharmaceuticals, Inc. has published a filing in the past twelve months. The most recent one dates from 18 December 2024.
The full history, which starts in 2021, counts 12 purchases against 6 sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€6M
12 ops. · all time
Sell Volume
€2M
6 ops. · all time
Who traded when
BuySaleJonathan C. Javitt1 buy
Analyst consensus: bullish or bearish?
Analysts rate NRX Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$38.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.85
Analyst consensus
4 analystsStrong buy
US$10.00Target US$38.50(+1251%)US$50.00
Income statement
RevenueUS$1.2M
Gross profitUS$720k59% margin
EBITDA-US$27.8M-2270% margin
Net income-US$28.6M-2336.5% margin
Valuation
PER (forward)-8.1x
Beta2.19
Balance sheet & cash
Market capUS$123.4M
Total debtUS$631k
Free Cash Flow-US$14.1M
Profitability & ownership
ROA-64.0%
% insiders4.1%
% institutions27.1%
Last declaration on 18 December 2024
Declarations34 total
40,000 shares@ US$1.170.7% of flowCommon StockSEC:0001415889-24-029694:0
Canonical exit: 17 Mar 2025 (T+90)
35,000 shares@ US$0.3199100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-23-013139:0
Canonical exit: 28 Nov 2023 (T+90)
70,000 shares@ US$0.28756.3% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-23-013137:0
Canonical exit: 28 Nov 2023 (T+90)
100,000 shares@ US$0.330.5% of flowCommon StockSEC:0001104659-23-094815:0
Canonical exit: 21 Nov 2023 (T+90)
200,000 shares@ US$0.3221.0% of flowCommon StockSEC:0001104659-23-094406:0
Canonical exit: 20 Nov 2023 (T+90)
50,000 shares@ US$1.17100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012654:0
Canonical exit: 16 Mar 2023 (T+90)
30,000 shares@ US$1.1076.8% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012652:0
Canonical exit: 16 Mar 2023 (T+90)
400,000 shares@ US$1.006.4% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012324:0
13,730 shares@ US$1.50411.8% of flowcommon stockSEC:0000880984-22-000017:0
2,500 shares@ US$1.25100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-011810:0
Canonical exit: 26 Feb 2023 (T+90)
8,716 shares@ US$1.1223.2% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-011778:0
Canonical exit: 23 Feb 2023 (T+90)
287,812 shares@ US$0.9993.7% of flowCommon StockSEC:0000950142-22-003233:0
Canonical exit: 14 Feb 2023 (T+90)
133,719 shares@ US$1.0211.6% of flowcommon stockSEC:0000880984-22-000015:0
49,200 shares@ US$1.00634.3% of flowcommon stockSEC:0000880984-22-000014:0
784,063 shares@ US$1.009468.4% of flowCommon StockSEC:0000880984-22-000009:0
2,000,000 shares0Common StockSEC:0000880984-22-000008:0
243,596 shares@ US$0.702414.0% of flowCommon StockSEC:0000880984-22-000007:0
100,000 shares@ US$58.0090.5% of flowCommon StockSEC:0000921895-22-001872:0
Canonical exit: 30 Aug 2022 (T+90)
100,000 shares@ US$0.580.9% of flowCommon StockSEC:0000921895-22-001874:0
Canonical exit: 30 Aug 2022 (T+90)
18,300 shares@ US$2.22100.0% of flowCommon StockSEC:0000950142-21-003506:0
63,710 shares@ US$0.20100.0% of flowCommon StockSEC:0000950142-21-003503:0
434,594 sharesCommon StockSEC:0000950142-21-003505:0
27,395 shares@ US$3.07100.0% of flowCommon StockSEC:0000950142-21-003504:0
8,336 sharesCommon StockSEC:0000950142-21-001941:0
1,436,350 sharesCommon StockSEC:0000950142-21-001942:0
25 of 34 declarations
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market under ticker NRXPW. Headquartered in Wilmington, Delaware, United States, the company is focused on severe psychiatric and central nervous system disorders with significant unmet medical need. Its business model is built around clinical development, regulatory execution, and eventual commercialization of therapies aimed at patients with severe depression, bipolar depression with suicidal ideation, PTSD, and related neuropsychiatric conditions.
NRx was founded around the premise of repurposing known molecules for high-value, high-need indications rather than relying solely on de novo drug discovery. That positioning has shaped the company into a specialist in interventional psychiatry. Its core programs center on NRX-100, a preservative-free intravenous ketamine product, and NRX-101, an oral combination therapy being developed for bipolar depression in patients with suicidal ideation and behavior. The company also references broader development efforts in PTSD and other severe mental health disorders.
Read moreShow less
From a competitive standpoint, NRx remains a small-cap, development-stage company, which means it carries materially higher execution and regulatory risk than large-cap pharmaceutical peers. Its potential strategic advantage lies in its narrow therapeutic focus, the use of known pharmacology, and the targeting of clinically urgent patient segments where treatment options remain limited. Management has pursued multiple regulatory paths, including both ANDA and NDA strategies, to broaden the probability of eventual approval and commercialization.
In parallel with its drug pipeline, NRx has launched HOPE Therapeutics, a subsidiary aimed at delivering integrated psychiatric care. That platform combines neuroplastic medications, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy, digital therapeutics, and medication management. This services-based layer could help the company build closer links with patients and prescribing physicians while creating a complementary commercial channel alongside its pharmaceutical pipeline.
Recent company developments are highly relevant for investors. During 2025 and into early 2026, NRx reported regulatory progress with the FDA on NRX-100, including Fast Track designation and discussions intended to identify a path toward broader approval. The company also said it had refiled an ANDA for preservative-free ketamine and was targeting an NDA filing around June 2026. For French-speaking investors, NRx should therefore be viewed as a speculative NASDAQ-listed U.S. healthcare name with a strong regulatory catalyst profile and meaningful dependence on FDA outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
